QCM Cayman’s Pacira BioSciences PCRX Stock Holding History

QCM Cayman’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-5,162	Closed	-$273K	–	340
2016 Q1	$273K	Buy	+5,162	New	+$302K	0.19%	96

Other funds holding PCRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

QCM Cayman's PCRX Position: Q2 2016 in Review

QCM Cayman sold out of Pacira BioSciences (PCRX) in Q2 2016, closing a stake of 5,162 shares — an estimated $273K sold.

QCM Cayman first reported a position in PCRX in Q1 2016 and held it in 1 quarter. The position peaked at $273K in Q1 2016. 183 funds tracked by Wall St. Rank hold PCRX as of Q2 2016.

QCM Cayman reported no remaining Pacira BioSciences position as of Q2 2016 after selling out during the quarter.
QCM Cayman sold 5,162 Pacira BioSciences shares in Q2 2016, an estimated $273K.
QCM Cayman first reported a position in Pacira BioSciences in Q1 2016 and held it in 1 quarter.
QCM Cayman's Pacira BioSciences position peaked at $273K in Q1 2016.
183 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2016.

Based on QCM Cayman's 13F filing for Q2 2016, filed 15 Aug 2016.